ReviewPreterm patent ductus arteriosus: A continuing conundrum for the neonatologist?
Introduction
A conundrum is defined as an intricate and difficult puzzle; how we should manage the preterm patent ductus arteriosus (PDA) is indeed a conundrum. On the one hand, there is evidence that the preterm PDA can be pathological. First, haemodynamic studies show that the PDA facilitates shunting of large volumes of blood from the systemic to the pulmonary circulation, draining blood from the former and overloading blood into the latter. Second, observational studies that have consistently associated persistent PDA shunting with a range of adverse outcomes including necrotizing enterocolitis (NEC), peri/intraventricular haemorrhage (P/IVH), chronic lung disease (CLD) and death [1], [2], [3]. Interpretation of these studies is limited by the co-linearity between each of these outcomes, persistent PDA and immaturity, and also by the wide range of ways in which PDA has been defined using a menagerie of clinical and, latterly, echocardiographic criteria [4].
On the other hand, since PDA is causing these adverse outcomes then treating it should reduce the incidence of those outcomes. Yet amalgamations of the results of randomized trials show little evidence of consistent effect of treating PDA on outcomes [5], [6], [7], [8]. However, again there are limitations in that, with the exception of prophylactic treatment, these trials are historically and methodologically diverse.
A purist interpretation of this conundrum would be that if treating makes no difference to outcomes then preterm PDA may not be pathological. However, lack of evidence of effect is not the same as evidence of lack of effect, and the other interpretation could be that we have not understood the natural history of the pathology of the PDA or what happens when we try to treat PDA medically. In other words, in many babies the treatment may not be doing what we want it to do.
Systematic review is important for defining the limitations of our understanding, but it is less useful for defining whether the right treatment questions have been asked in the right way. For that, you have to study the babies and their ducts with the goal of understanding what is pathological and what is not pathological about their behaviour. Good treatment strategies still depend on accurate diagnosis and an understanding of the natural history of the pathophysiology.
Section snippets
Cardiac ultrasound and the ductus
Cardiac ultrasound has been pivotal to the development of our understanding about the ductus. Ultrasound allows direct imaging of the ductus, assessment of constriction, the shunt direction and velocity, and the disturbance to blood flow patterns in the great vessels either side of the ductus (Fig. 1).
Treatment of the preterm ductus arteriosus
So should we be treating PDA in preterm babies? It has been apparent for many years from systematic review of the literature that there is no clear evidence of effect on long-term outcomes of treating PDA. The issue has been brought into sharper focus by several review articles, which have essentially re-worked the same studies and, perhaps not surprisingly, have failed to produce a clear answer. Laughon and Bose [5], [6] proposed that the reason for the lack of effect might be that the patency
If you are going to treat, when to treat?
This is the really difficult part. There are essentially three strategies that have been studied. The first is to wait to see if the PDA becomes clinically apparent (e.g murmur, bounding pulses or active praecordium) and/or symptomatic (e.g. respiratory deterioration or ventilator dependence) and then treat. Despite being probably the commonest strategy in clinical practice, the studies of this symptomatic approach are surprisingly limited. Second is pre-symptomatic treatment; these studies
What is the role of surgical ligation?
Although few centres would use surgical ligation as a first-line treatment, it is still used in babies who fail to respond to medical treatment and who continue to have medical conditions potentially attributable to the presence of a large PDA. There appears to be an international trend to a less aggressive approach to ductal ligation, reflecting concerns that ligation of PDA may do more harm than good [40]. Several studies have shown acute, potentially detrimental, hemodynamic effects after
How should PDA be managed in 2015?
All this hand-wringing over the evidence is not particularly helpful to the practising clinician who wants to know what to do. Despite all the copy decrying our lack of understanding of treatment of PDA, the proposed trials remain elusive because they are so difficult to perform.
It could be argued that, if you were an evidence-based purist, then you should either never treat any PDA in any baby or you should use prophylactic indomethacin. It would be my opinion that the former should be applied
What next: very early ultrasound targeted treatment?
Few would argue about the need for more trials of PDA therapy, but in the real world, rightly or wrongly, many clinicians have difficulty accepting no treatment in individual babies with significant PDA. There have been proposals to compare conventional treatment of PDA after a few days, either symptomatically or pre-symptomatically, with a control group where the aim would be that almost no babies receive treatment. It is my understanding that these trials have floundered on clinician
Conflict of interest statement
None declared.
Funding sources
None.
References (43)
- et al.
High pulmonary blood flow, the duct and pulmonary haemorrhage
J Pediatr
(2000) - et al.
Short vs prolonged indomethacin therapy for patent ductus arteriosus in preterm infants
J Pediatr
(1999) - et al.
Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus – a double-blind controlled study
J Pediatr
(1981) - et al.
Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial
J Pediatr
(1981) - et al.
Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study
J Pediatr
(1983) - et al.
Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome
J Pediatr
(2001) - et al.
Patent ductus arteriosus ligation is associated with impaired left ventricular systolic performance in premature infants weighing less than 1000 g
J Thoracic Cardiovasc Surg
(2010) - et al.
Changes in myocardial function and hemodynamics after ligation of the ductus arteriosus in preterm infants
J Pediatr
(2007) - et al.
Early significant ductal shunting and intraventricular haemorrhage in ventilated preterm infants
Archs Dis Childh
(1996) - et al.
Failure of ductus arteriosus closure is associated with increased mortality in preterm infants
Pediatrics
(2009)
The definition of a hemodynamic significant duct in randomised controlled trials, a systematic literature review
J Paediatr Child Health
Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated?
Curr Opin Pediatr
Patent ductus arteriosus: lack of evidence for common treatments
Archs Dis Childh Fetal Neonatal Ed
Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?
J Perinatol
Patent ductus arteriosus: to treat or not to treat?
Archs Dis Childh Fetal Neonatal Ed
Postnatal circulatory adaptation in term and healthy preterm newborns
Archs Dis Childh
Neonatal pulmonary ischaemia. Part 1: clinical and physiological studies
Pediatrics
Low superior vena cava flow and intraventricular haemorrhage in preterm infants
Archs Dis Childh
Does retrograde diastolic flow in the descending aorta signify impaired systemic perfusion in preterm infants?
Pediatr Res
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants
Cochrane Database Syst Rev
An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study
Br J Clin Pharmacol
Cited by (98)
Combination therapy for patent ductus arteriosus in preterm infants: Echocardiographic changes and clinical use
2023, Progress in Pediatric CardiologyInternational Variation in the Management of Patent Ductus Arteriosus and Its Association with Infant Outcomes: A Survey and Linked Cohort Study
2022, Journal of PediatricsCitation Excerpt :Although this practice may enable the adjustment of dosing regimens during the treatment course, its effectiveness to reduce medication-related adverse effects is yet to be studied. Controversies regarding whether and how to treat PDA persist.1-3 This uncertainty may explain the wide variation in PDA management found both across and within the iNeo networks in this study.
Management of the infant with bronchopulmonary dysplasia
2022, Goldsmith's Assisted Ventilation of the Neonate: An Evidence-Based Approach to Newborn Respiratory Care, Seventh EditionReference intervals for preterm thyroid function during the fifth to seventh day of life
2021, Clinical BiochemistryCitation Excerpt :The Apgar scores of the included preterm neonates were greater than or equal to 7 points at 5 min. Preterm neonates who were exposed to iodine, diagnosed with diseases (e.g., CH [2], symptomatic patent ductus arteriosus (PDA) [11], NRDS [12], sepsis [13], tumor) or died within one year after birth were excluded. Tumors included hemangioma, lymphangioma or teratoma, neuroblastoma, or Wilms tumor.